for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Minerva Neurosciences Inc

NERV.O

Latest Trade

8.01USD

Change

-0.47(-5.54%)

Volume

330,757

Today's Range

7.62

 - 

8.49

52 Week Range

4.01

 - 

9.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Minerva Neurosciences Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER

BRIEF-Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results

* MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

* Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

BRIEF-Minerva Neurosciences Q2 loss per share $0.27

* Minerva Neurosciences reports second quarter 2017 financial results and business updates

BRIEF-American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results

* American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia

BRIEF-Minerva Neurosciences announces departure of directors

* Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen

BRIEF-Minerva Neurosciences announces departure of directors

* Minerva Neurosciences announces departure of directors Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences prices 5 mln common shares at $7.75 per share

* Minerva neurosciences announces pricing of public offering of common stock

BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

* Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

BRIEF-Minerva Neurosciences enters amendment to co-development and license agreement with Janssen Pharmaceutica NV

* Minerva Neurosciences - on June 13, co entered amendment to co-development and license agreement between company and Janssen Pharmaceutica NV

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up